The potential of proton beam radiation therapy in prostate cancer, other urological cancers and gynaecological cancers

Acta Oncologica

Volumn 44, Issue 8, 2005, Pages 890-895

  Johansson, Bengt ^a   Ridderheim, Mona ^b   Glimelius, Bengt ^c,d  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; BEAM THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; GYNECOLOGIC CANCER; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROTON RADIATION; RADIATION DEPTH DOSE; RADIATION DOSE DISTRIBUTION; REVIEW; SCREENING TEST; TREATMENT OUTCOME; URINARY TRACT CARCINOMA;

COST-BENEFIT ANALYSIS; FEMALE; GENITAL NEOPLASMS, FEMALE; HEALTH CARE COSTS; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTONS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; SWEDEN; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS;

EID: 28844498021     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860500355942     Document Type: Review

References (61)

1. Cancer Incidence in Sweden. Epidemiologiskt Centrum 2003; www.sos.se.
2. Albertsen PC. Is screening for prostate cancer with prostate specific antigen an appropriate public health measure? Acta Oncol 2005;44:255-64.
3. Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Haggman M, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002;347:781-9.
4. Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352:1977-84.
5. Johansson JE, Andren O, Andersson SO, Dickman PW, Holmberg L, HO A. Natural history of early, localized prostate cancer. JAMA 2004;291:2713-9.
6. Glimelius B, Steineck G. Low evidence of radiation therapy in prostate cancer-a plea for intensified scientific activity. Acta Oncol 2004;43:311-5.
7. Nilsson S, Widmark A, Norlén BJ. A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol 2004;43:316-81.
8. Albertsen PC, Nease RF, Jr, Potosky AL. Assessment of patient preferences among men with prostate cancer. J Urol 1998;159:158-63.
9. Saigal CS, Gornbein J, Reid K, Litwin MS. Stability of time trade-off utilities for health states associated with the treatment of prostate cancer. Qual Life Res 2002;11:405-14.
10. Krahn M, Ritvo P, Irvine J, Tomlinson G, Bremner KE, Bezjak A, et al. Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. Med Care 2003;41:153-64.
11. Foroudi F, Tyldesley S, Barbera L, Huang J, Mackillop WJ. Evidence-based estimate of appropriate radiotherapy utilization rate for prostate cancer. Int J Radiat Oncol Biol Phys 2003;55:51-63.
12. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002;53:1097-105.
13. Cheung R, Tucker SL, Lee AK, de Crevoisier R, Dong L, Kamat A, et al. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 2005;61:993-1002.
14. Damber J-E. Endocrine therapy for prostate cancer. Acta Oncol 2005;44:605-9.
15. Möller TR, Einhorn N, Lindholm C, Nyhlén U, Svensson S, for the SBU Survey Group. Radiotherapy techniques in current use in Sweden. Acta Oncol 2003;42:376-86.
16. Hanlon AL, Watkins Bruner D, Peter R, Hanks GE. Quality of life study in prostate cancer patients treated with three-dimensional conformal radiation therapy: Comparing late bowel and bladder quality of life symptoms to that of the normal population. Int J Radiat Oncol Biol Phys 2001;49:51-9.
17. Zelefsky MJ, Wallner KE, Ling CC, Raben A, Hollister T, Wolfe T, et al. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J Clin Oncol 1999;17:517-22.
18. Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC, et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 2002;53:1111-6.
19. Kupelian PA, Reddy CA, Carlson TP, Willoughby TR. Dose/volume relationship of late rectal bleeding after external beam radiotherapy for localized prostate cancer: absolute or relative rectal volume? Cancer J 2002;8:62-6.
20. Kupelian PA, Reddy CA, Carlson TP, Altsman KA, Willoughby TR. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer. Int J Radiat Oncol Biol Phys 2002;53:904-12.
21. Gardner BG, Zietman AL, Shipley WU, Skowronski UE, McManus P. Late normal tissue sequelae in the second decade after high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer. J Urol 2002;167:123-6.
22. al-Abany M, Helgason AR, Cronqvist AK, Svensson C, Wersall P, Steineck G. Long-term symptoms after external beam radiation therapy for prostate cancer with three or four fields. Acta Oncol 2002;41:532-42.
23. Widmark A, Fransson P, Tavelin B. Self-assessment questionnaire for evaluating urinary and intestinal late side effects after pelvic radiotherapy in patients with prostate cancer compared with an age-matched control population. Cancer 1994;74:2520-32.
24. Dearnaley DP, Khoo VS, Norman AR, Meyer L, Nahum A, Tait D, et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 1999;353:267-72.
25. Lilleby W, Fossa SD, Waehre HR, Olsen DR. Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy. Int J Radiat Oncol Biol Phys 1999;43:735-43 (R1/154).
26. Chism DB, Horwitz EM, Hanlon AL, Pinover WH, Mitra RK, Hanks GE. Late morbidity profiles in prostate cancer patients treated to 79-84 Gy by a simple four-field coplanar beam arrangement. Int J Radiat Oncol Biol Phys 2003;55:71-7.
27. Huang EH, Pollack A, Levy L, Starkschall G, Dong L, Rosen I, et al. Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2002;54:1314-21.
28. Schultheiss TE, Lee WR, Hunt MA, Hanlon AL, Peter RS, Hanks GE. Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 1997;37:3-11.
29. Crook J, Esche B, Futter N. Effect of pelvic radiotherapy for prostate cancer on bowel, bladder, and sexual function: the patient's perspective. Urology 1996;47:387-94.
30. Peeters ST, Heemsbergen WD, van Putten WL, Slot A, Tabak H, Mens JW, et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 2005;61:1019-34.
31. Heemsbergen WD, Hoogeman MS, Hart GA, Lebesque JV, Koper PC. Gastrointestinal toxicity and its relation to dose distributions in the anorectal region of prostate cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 2005;61:1011-8.
32. al-Abany M, Helgason AR, Cronqvist AK, Lind B, Mavroidis P, Wersall P, et al. Toward a definition of a threshold for harmless doses to the anal-sphincter region and the rectum. Int J Radiat Oncol Biol Phys 2005;61:1035-44.
33. Morris DE, Emami B, Mauch PM, Konski AA, Tao ML, Ng AK, et al. Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiative. Int J Radiat Oncol Biol Phys 2005;62:3-19.
34. Slater JD, Rossi CJ, Jr, Yonemoto LT, Bush DA, Jabola BR, Levy RP, et al. Proton therapy for prostate cancer: the initial Loma Linda University experience. Int J Radiat Oncol Biol Phys 2004;59:348-52.
35. Schulte RW, Slater JD, Rossi CJ, Slater JM. Value and perspectives of proton radiation therapy for limited stage prostate cancer. Strahlenther Onkol 2000;176:3-8.
36. Shipley WU, Verhey LJ, Munzenrider JE, Suit HD, Urie MM, McManus PL, et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys 1995;32:3-12.
37. Ishikawa H, Tsuji H, Kamada T, Yanagi T, Wakatsuki M, Dhimazaki J, et al. A phase II trial using carbon ion radiotherapy (C-ion RT) for prostate cancer. Proc Am Soc Clin Oncol 2005:Abstr 4630.
38. Lee M, Wynne C, Webb S, Nahum AE, Dearnaley D. A comparison of proton and megavoltage X-ray treatment planning for prostate cancer. Radiother Oncol 1994;33:239-53.
39. Cella L, Lomax A, Miralbell R. Potential role of intensity modulated proton beams in prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 2001;49:217-23.
40. Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, et al. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys 2005;61:415-9.
41. Lundkvist J, Ekman M, Rehn Ericsson S, Jönsson B, Glimelius B. Proton therapy of cancer: Potential clinical advantages and cost-effectiveness. Acta Oncol 2005;44:850-61.
42. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999;43:1095-101.
43. Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour EP. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002;52:6-13.
44. Fowler JF. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol 2005;44:265-76.
45. Widmark A, Flodgren P, Damber J, Hellsten S, Cavallin-Stahl E. A systematic overview of radiation therapy effects in urinary bladder cancer. Acta Oncol 2003;42:567-81.
46. Muren LP, Smaaland R, Dahl O. Conformal radiotherapy of urinary bladder cancer. Radiother Oncol 2004;73:387-98.
47. Shelley MD, Barber J, Wilt T, Mason MD. Surgery versus radiotherapy for muscle invasive bladder cancer. Cochrane Database Syst Rev 2002:CD002079.
48. Möller TR, Brorsson B, Ceberg J, Frodin JE, Lindholm C, Nylen U, et al. A prospective survey of radiotherapy practice 2001 in Sweden. Acta Oncol 2003;42:387-410.
49. Battermann JJ. Results of d+T fast neutron irradiation on advanced tumors of bladder and rectum. Int J Radiat Oncol Biol Phys 1982;8:2159-64.
50. Duncan W, Williams JR, Kerr GR, Arnott SJ, Quilty PM, Rodger A, et al. An analysis of the radiation related morbidity observed in a randomized trial of neutron therapy for bladder cancer. Int J Radiat Oncol Biol Phys 1986;12:2085-92.
51. Errington RD, Ashby D, Gore SM, Abrams KR, Myint S, Bonnett DE, et al. High energy neutron treatment for pelvic cancers: study stopped because of increased mortality. Bmj 1991;302:1045-51.
52. Pointon RS, Read G, Greene D. A randomised comparison of photons and 15 MeV neutrons for the treatment of carcinoma of the bladder. Br J Radiol 1985;58:219-24.
53. Einhorn N, Trope C, Ridderheim M, Boman K, Sorbe B, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in uterine cancer (corpus uteri). Acta Oncol 2003;42:557-61.
54. Einhorn N, Trope C, Ridderheim M, Boman K, Sorbe B, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in ovarian cancer. Acta Oncol 2003;42:562-6.
55. Einhorn N, Trope C, Ridderheim M, Boman K, Sorbe B, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in cervical cancer (cervix uteri). Acta Oncol 2003;42:546-56.
56. Sténson S. Effects of high-energy protons on healthy organs and malignant tumours. Including a study of radiation protection by local hypoxia.: Thesis. Uppsala University; 1969.
57. Arimoto T, Kitagawa T, Tsujii H, Ohhara K. High-energy proton beam radiation therapy for gynecologic malignancies. Potential of proton beam as an alternative to brachytherapy. Cancer 1991;68:79-83.
58. Tsujii H, Tsuji H, Inada T, Maruhashi A, Hayakawa Y, Takada Y, et al. Clinical results of fractionated proton therapy. Int J Radiat Oncol Biol Phys 1993;25:49-60.
59. Kagei K, Tokuuye K, Okumura T, Ohara K, Shioyama Y, Sugahara S, et al. Long-term results of proton beam therapy for carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 2003;55:1265-71.
60. Molla M, Escude L, Nouet P, Popowski Y, Hidalgo A, Rouzaud M, et al. Fractionated stereotactic radiotherapy boost for gynecologic tumors: an alternative to brachytherapy? Int J Radiat Oncol Biol Phys 2005;62:118-24.
61. Suit HD, Becht J, Leong J, Stracher M, Wood WC, Verhey L, et al. Potential for improvement in radiation therapy. Int J Radiat Oncol Biol Phys 1988;14:777-86.